Shearman & Sterling advised the underwriters of Pulmonx Corporation’s initial public offering of 11,500,000 shares of common stock at a public offering price of $19.00 per share, resulting in gross proceeds to the Company of approximately $218.5 million, before deducting underwriting discounts and commissions and offering expenses. The 11,500,000 shares included 1,500,000 of shares issued pursuant to the underwriters’ option to purchase additional shares. The shares began trading on The Nasdaq Global Select Market under the ticker symbol “LUNG” on October 1, 2020.
BofA Securities and Morgan Stanley acted as joint lead book-running managers for the offering and Stifel, Wells Fargo Securities and Canaccord Genuity acted as lead managers.
Pulmonx Corporation is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema.